I'm betting on this one and it's not too far off.

https://clinicaltrials.gov/ct2/show/NCT04840589 

Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694:

Testing the Combination of ZEN003694 and Nivolumab (OPDIVO) With or Without Ipilimumab (YERVOY) in Solid Tumors, with  36 Participants with an estimated study completion date, Jan 1, 2023.

https://agoracom.com/ir/ZenithEpigenetics/forums/discussion/topics/774323-news-out-dosing-of-first-cancer-patient-with-a-combination-of-zen-3694-bristol-myers-squibb-s-immune-checkpoint-inhibitor-opdiv/messages/2348433#message

Koo